Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Atara Biotherapeutics (NASDAQ:ATRA) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM.
Here's what investors need to know about the announcement.
Atara Biotherapeutics missed estimated earnings by -17.0%, reporting an EPS of $-0.56 versus an estimate of $-0.48.
Revenue was up $4.03 million from the same period last year.
Last quarter the company missed on EPS by $0.0 which was followed by a 6.0% drop in the share price the next day.
Here's a look at Atara Biotherapeutics's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 |
---|---|---|---|
EPS Estimate | -0.66 | -0.67 | -0.39 |
EPS Actual | -0.66 | -0.68 | -0.72 |
Revenue Estimate | 4.76M | 3.77M | 30.68M |
Revenue Actual | 2.14M | 957K | 1.23M |
To track all earnings releases for Atara Biotherapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ATRA